ArticleNPJ precision oncology2022

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.

Wenjing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.